Gibson Dunn Advises Shareholders in Connection with Sale of Aicuris to Asahi Kasei
Firm News | February 27, 2026
Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc. The acquisition price amounts to 780 million euros (approximately $920 million USD).
Gibson Dunn regularly advises shareholders and life sciences companies on complex cross-border M&A transactions in the pharmaceutical sector.
The Gibson Dunn M&A team was led by Dr. Dirk Oberbracht and Sonja Ruttmann and included Ryan Murr, Dr. Aliresa Fatemi, Simon Stöhlker, Andreas Rief, Tim Windfelder, and David Lübkemeier. Dr. Lars Petersen, Kai Gesing, and Yannick Oberacker advised on regulatory and antitrust. Sean Feller advised on tax. Dr. Peter Gumnior advised on labor law aspects.